| FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 T Brevini, M Maes, GJ Webb, BV John, CD Fuchs, G Buescher, L Wang, ... Nature 615 (7950), 134-142, 2023 | 240 | 2023 |
| Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies JA Heslop, TG Hammond, I Santeramo, A Tort Piella, I Hopp, J Zhou, ... Stem cells translational medicine 4 (4), 389-400, 2015 | 149 | 2015 |
| Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile JA Heslop, C Rowe, J Walsh, R Sison-Young, R Jenkins, L Kamalian, ... Archives of toxicology 91, 439-452, 2017 | 141 | 2017 |
| Stem cell‐derived hepatocytes as a predictive model for drug‐induced liver injury: are we there yet? R Kia, RLC Sison, J Heslop, NR Kitteringham, N Hanley, JS Mills, BK Park, ... British Journal of Clinical Pharmacology 75 (4), 885-896, 2013 | 98 | 2013 |
| GATA6 defines endoderm fate by controlling chromatin accessibility during differentiation of human-induced pluripotent stem cells JA Heslop, B Pournasr, JT Liu, SA Duncan Cell reports 35 (7), 2021 | 52 | 2021 |
| MicroRNA-122: A Novel Hepatocyte-Enriched in vitro Marker of Drug-Induced Cellular Toxicity R Kia, L Kelly, RLC Sison-Young, F Zhang, CS Pridgeon, JA Heslop, ... Toxicological Sciences 144 (1), 173-185, 2015 | 47 | 2015 |
| Human pluripotent stem cells for modeling toxicity RLC Sison-Young, R Kia, J Heslop, L Kelly, C Rowe, MJ Cross, ... Advances in pharmacology 63, 207-256, 2012 | 28 | 2012 |
| The use of human pluripotent stem cells for modeling liver development and disease JA Heslop, SA Duncan Hepatology 69 (3), 1306-1316, 2019 | 25 | 2019 |
| Donor-dependent and other nondefined factors have greater influence on the hepatic phenotype than the starting cell type in induced pluripotent stem cell derived hepatocyte … JA Heslop, R Kia, CS Pridgeon, RL Sison-Young, T Liloglou, M Elmasry, ... Stem cells translational medicine 6 (5), 1321-1331, 2017 | 25 | 2017 |
| FoxA factors: the chromatin key and doorstop essential for liver development and function JA Heslop, SA Duncan Genes & development 34 (15-16), 1003-1004, 2020 | 15 | 2020 |
| PDE5 inhibition rescues mitochondrial dysfunction and angiogenic responses induced by Akt3 inhibition by promotion of PRC expression DG Corum, DP Jenkins, JA Heslop, LM Tallent, GC Beeson, JL Barth, ... Journal of Biological Chemistry 295 (52), 18091-18104, 2020 | 12 | 2020 |
| Enhanced genome editing in human iPSCs with CRISPR-CAS9 by co-targeting ATP1a1 JT Liu, JL Corbett, JA Heslop, SA Duncan PeerJ 8, e9060, 2020 | 12 | 2020 |
| Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of In Vitro Models C Goldring, A Norris, N Kitteringham, MD Aleo, DJ Antoine, J Heslop, ... Applied in Vitro Toxicology 1 (3), 175-186, 2015 | 9 | 2015 |
| Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability. Sci. Rep. 6, 35434 DFG Hendriks, L Fredriksson Puigvert, S Messner, W Mortiz, ... | 6 | 2016 |
| A human iPSC-derived hepatocyte screen identifies compounds that inhibit production of Apolipoprotein B JT Liu, C Doueiry, Y Jiang, J Blaszkiewicz, MP Lamprecht, JA Heslop, ... Communications Biology 6 (1), 452, 2023 | 4 | 2023 |
| Chromatin remodeling is restricted by transient GATA6 binding during iPSC differentiation to definitive endoderm JA Heslop, B Pournasr, SA Duncan Iscience 25 (5), 2022 | 3 | 2022 |
| Single-Cell Transcriptomic Profiling of Cholangiocyte Organoids Derived from Bile Ducts of Primary Sclerosing Cholangitis Patients AK Frank, BK Chung, MLL De Novales, LK Engesæter, HW Hoyle, ... Digestive Diseases and Sciences 69 (10), 3810-3823, 2024 | 2 | 2024 |
| Application of pluripotent stem cells in drug‐induced liver injury safety assessment CS Pridgeon, F Zhang, JA Heslop, CML Nugues, NR Kitteringham, ... Drug Discovery Toxicology: From Target Assessment to Translational …, 2016 | 1 | 2016 |
| LBP-008 AAV8 gene therapy for mitochondrial neurogastrointestinal encephalomyopathy T Brevini, L Swift, H Reynolds, R Stopforth, Y Malam, J Ong, H Spiers, ... Journal of Hepatology 80, S81, 2024 | | 2024 |
| iPSC-derived hepatocytes as a novel tool for glycogen storage disease 1A (GSD1A) modelling and drug screening N Nikolaou, M Aksoy, K Cheung, S Chung, J Heslop, C Gil, L Panman Endocrine Abstracts 86, 2022 | | 2022 |